Pharvaris N.V. Files June 2024 6-K Report

TL;DR

Pharvaris N.V. (PHVS) filed a routine 6-K, confirming its status as a foreign private issuer.

AI Summary

Pharvaris N.V. filed a Form 6-K on June 4, 2024, to report information for the month of June 2024. The company is a foreign private issuer and files annual reports under Form 20-F. Its principal executive office is located at Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands.

Why It Matters

This filing indicates Pharvaris N.V. is fulfilling its reporting obligations as a foreign private issuer with the SEC, providing transparency to investors.

Risk Assessment

Risk Level: low — This filing is a standard procedural report and does not contain new financial or operational information that would typically increase risk.

Key Players & Entities

• Pharvaris N.V. (company) — Registrant
• 001-40010 (company) — Commission File Number
• Form 20-F (company) — Annual Report Form
• Form 6-K (company) — Filing Type

FAQ

From the Filing

0000950170-24-068649.txt : 20240604 0000950170-24-068649.hdr.sgml : 20240604 20240604160502 ACCESSION NUMBER: 0000950170-24-068649 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240604 FILED AS OF DATE: 20240604 DATE AS OF CHANGE: 20240604 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharvaris N.V. CENTRAL INDEX KEY: 0001830487 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40010 FILM NUMBER: 241017901 BUSINESS ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 BUSINESS PHONE: 31 (0)71 203 6410 MAIL ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Pharvaris, B.V. DATE OF NAME CHANGE: 20201029 6-K 1 6-k_pr_june_4_2024.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of June 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2   2333 BK Leiden   The Netherlands (Address of principal executive office)   Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐   Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐   Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.   PHARVARIS N.V.   On June 4, 2024, Pharvaris N.V. issued a press release. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. This Report on Form 6-K (including Exhibit 99.1) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Numbers 333-278650, 333-277705 and 333-273757) and Form S-8 (Registration Number 333-252897).   SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   PHARVARIS N.V.     Date: June 4, 2024 By: /s/ Berndt Modig   Name: Berndt Modig   Title: Chief Executive Officer   EXHIB INDEX   Exhibit No.   Description 99.1   Press Release dated June 4, 2024.   EX-99.1 2 phvs-ex99_1.htm EX-99.1 EX-99.1     Exhibit 99.1 Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses • Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hours • Hi